Aktiesnakken — Oktober 2009
-
Rt på genmab
-
142,25
-
142,25 ufatteligt
-
Den ynkeligste FDA godkendelse siden vi gik over til agerbrug
-
UBS og CSFB er de helt store slyngler
-
HER går det ihvertfald godt http://www.americanchronicle.com/articles/yb/136977286
-
Der hvor jeg kommer fra i Jylland er det såmænd ikke så længe siden. Spørg blot stengård
-
ser ud til 1,5 times Vestas cc har haft en mindre positiv virkning på kursen
-
ham DE er nu ellers god til at glide af på de nærgående spørgsmål
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind